In our study cohort, comparative analysis of pathological subgroups revealed significantly lower serum chemerin levels in MS patients when compared to neurologically healthy individuals, both with and without matching for age, sex and BMI, whereas chemerin levels in CSF were unchanged in MS compared to matched controls. The gene discussed is RARRES2; the disease is myeloid sarcoma.